Следующий

Автовоспроизведение

60-Second Journal Club: Vutrisiran in ATTR Amyloidosis with Cardiomyopathy

0 Просмотры • 06/06/25
Поделиться
встраивать
administrator
administrator
Подписчики
0

Transthyretin amyloidosis, also called ATTR amyloidosis, is a progressive, fatal disease caused by misfolded transthyretin (TTR) protein that accumulates as amyloid fibrils in multiple organs, commonly leading to cardiomyopathy.

In the HELIOS-B trial, researchers assessed the efficacy and safety of vutrisiran, an RNA interference therapeutic that inhibits the synthesis of transthyretin, in patients with ATTR amyloidosis with cardiomyopathy. NEJM Editorial Fellow Christos Kotanidis, MD, DPhil, summarizes the results in this 60-Second Journal Club.

Read the full study: https://nej.md/3X5nl5Q

#cardiology #cardiomyopathy #genetherapy #clinicaltrials #nejm

Показать больше
0 Комментарии sort Сортировать по
Комментарии Facebook

Следующий

Автовоспроизведение